-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Show Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Sponsor: Incyte Corporation, Mallinckrodt Pharmaceuticals, and Sanofi
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Drug development, Education, Treatment Considerations, Adverse Events
Friday, December 6, 2024: 7:00 PM-10:00 PM
Room 6A (San Diego Convention Center)
Chair:
Corey S. Cutler, MD, MPH, ARRAY(0xf5c56f4)
Disclosures:
Cutler: Oxford Immune Algorithmics: Current equity holder in private company; Cimeio: Current equity holder in publicly-traded company; Astellas: Consultancy; Incyte: Consultancy; Syndax: Consultancy; Sanofi: Consultancy; Novartis: Consultancy; Rigel: Consultancy; Angiocrine: Other: DSMB; Allovir: Other: DSMB.
Speakers:
Amin M. Alousi, MD, The University of Texas MD Anderson Cancer Center , Yi-Bin Chen, MD, MS, Harvard Medical School and Carrie L. Kitko, MD, ARRAY(0xfa064b8)
Disclosures:
Chen: Incyte: Consultancy; Vor: Consultancy; CSL Behring: Consultancy; Ironwood: Consultancy; MaaT Bio: Consultancy; Novo Nordisk: Consultancy; Editas: Consultancy; ImmunoFree: Consultancy. Kitko: Incyte corp.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees.

On Demand program will be available here December 7, 2024.

Access Program Here

The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with graft versus host disease (GvHD) with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.

See more of: Friday Satellite Symposia
<< Previous Application | Next Application >>